NHSG/PGD/lido_eton/MGPG412 Organisation Wide
|
|
- Dylan Booker
- 8 years ago
- Views:
Transcription
1
2 Title: Patient Group Direction For The Administration Of Lidocaine 2% Injection For The Insertion/Removal Of The 68mg Etonogestrel Contraceptive Implant By Nurses And Midwives Working Within NHS Grampian Identifier: NHSG/PGD/lido_eton/MGPG562 Replaces: Across NHS Boards NHSG/PGD/lido_eton/MGPG412 Organisation Wide Directorate Clinical Service Sub Department Area Yes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative. Author: Subject Key word(s): Policy application: Purpose: CHP Lead Pharmacist Patient Group Direction PGD patient group direction nurse midwife lidocaine injection etonogestrel contraception NHS Grampian This Patient Group Direction (PGD) authorises appropriately qualified and trained nurses and midwives to administer lidocaine injection 2% for the insertion/removal of the 68mg etonogestrel contraceptive implant to individuals without the requirement for a patient specific prescription written by a medical practitioner. Responsibilities for implementation: Organisational: Corporate: Departmental: Area: Hospital/Interface services: Operational Management Unit: Policy statement: Review: Chief Executive and Management Teams Senior Managers Heads of Service/Clinical Leads Line Managers Assistant General Managers and Group Clinical Directors Unit Operational Managers It is the responsibility of individual nurses and midwives and their line managers to ensure that they work within the terms laid down in this PGD and to ensure that staff are working to the most up to date PGD. By doing so, the quality of the services offered will be maintained, and the chances of staff making erroneous decisions which may affect patient, staff or visitor safety and comfort will be reduced. Supervisory staff at all levels must ensure that staff using this PGD act within their own level of competence. This policy will be reviewed at least every two years or sooner if current treatment recommendations change. UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG562 - i -
3 This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) or (01224) Responsible for review of this document: Responsible for ensuring registration of this document on the NHS Grampian Information/ Document Silo: Physical location of the original of this document: Job/group title of those who have control over this document: Responsible for disseminating document as per distribution list: CHP Lead Pharmacist Medicines Management Pharmacist Pharmacy and Medicines Directorate CHP Lead Pharmacist CHP Lead Pharmacist Revision History: Date of Approval change date of PGD that is being Summary of Changes Section heading superseded Jan 2013 Jan yearly update into new template Mar 2013 Jan 2011 Addition of injection to title Throughout Mar 2013 Jan 2011 Use only for implant insertion/removal added Purpose UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG562 - ii -
4 Patient Group Direction For The Administration Of Lidocaine 2% Injection For The Insertion/Removal Of The 68mg Etonogestrel Contraceptive Implant By Nurses And Midwives Working Within NHS Grampian Contents Part A Specific Drug Information Page No 1 Introduction 2 2 Clinical Decision Making Patients who may be considered for the administration of lidocaine 2 2% injection 2.2 Patients who may receive the administration of lidocaine 2% injection Contraindications Precautions Action to be taken when a patient is excluded from treatment under 3 this PGD 2.6 Action to be taken when a patient does not wish to receive treatment 3 under this PGD 3 Description Of Treatment Available Under This PGD Lidocaine 2% Injection Dose, route and frequency Concurrent medication Adverse effects Advice to patient Follow up treatment 5 Part B PGD General Information 4 Designated Staff Authorised To Administer Under This PGD 6 5 Documentation Authorisation of administration Record of administration Consent 8 6 Further Points 8 7 Facilities And Supplies To Be Available At Sites For The 8 Administration Of The Drug Specified In The PGD 8 Audit 8 Part C PGD Specific Information 9 Management And Monitoring Of Patient Group Direction Consultative group Professional advisory group approving PGD Authorising managers 9 10 References 9 Appendix 1 - Health Care Professional Agreement To Administer 10 Medicines Under Patient Group Direction Appendix 2 - Certificate Of Competence To Administer Medicines Under Patient Group Direction 11 UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
5 Patient Group Direction For The Administration Of Lidocaine 2% Injection For The Insertion/Removal Of The 68mg Etonogestrel Contraceptive Implant By Nurses And Midwives Working Within NHS Grampian 1. Introduction Part A This patient group direction (PGD) will allow nurses and midwives to be authorised to subcutaneously administer lidocaine 2% injection to individuals prior to the removal or insertion of the 68mg etonogestrel contraceptive implant. This PGD should be used in conjunction with the PGD for the insertion of the 68mg etonogestrel contraceptive implant which is available under PGD for women aged from 14 years up to and including 49 years. This PGD should be used in conjunction with the recommendations in the current British National Formulary and individual Summary of Product Characteristics. 2. Clinical Decision Making 2.1. Patients who may be considered for the administration of lidocaine 2% injection Women who require the insertion or removal of the 68mg etonogestrel contraceptive implant Patients who may receive the administration of lidocaine 2% injection All patients in 2.1 above, who do not want specifically to consult with a doctor and are willing to have treatment from the nurse or midwife 2.3. Contraindications Patients may be administered lidocaine 2% injection under this PGD unless they have known anaphylactic hypersensitivity to lidocaine or any of the excipients. Also, under this PGD, subcutaneous lidocaine 2% injection for 68mg etonogestrel contraceptive implant insertion/removal should not be administered to patients with the following personal or medication history: (i) Age less than 14 years. (ii) Current venous thrombosis/thromboembolism. (iii) Porphyria. UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
6 (iv) Previous adverse reaction to local anaesthesia. A careful history of reason for the previous local anaesthesia and exact adverse reaction must be taken. (v) Medication as detailed in Section Precautions Lidocaine should be used with caution in patients with: epilepsy, impaired cardiac conduction, congestive cardiac failure, bradycardia or impaired respiratory function and impaired hepatic function Action to be taken when a patient is excluded from treatment under this PGD If a patient is excluded from treatment under this PGD, medical advice should be sought refer to a doctor Action to be taken when a patient does not wish to receive treatment under this PGD The patient should be advised of the risks of not receiving the administration of lidocaine 2%. The 68mg etonogestrel contraceptive implant insertion or removal should not proceed under PGD. 3. Description Of Treatment Available Under This Direction 3.1. Lidocaine 2% Injection Lidocaine 2% is a Prescription-only Medicine (PoM). Lidocaine 2% is an amide local anaesthetic. It is supplied as a clear solution in sterile ampoules. Lidocaine 2% injection without adrenaline should be used under this PGD Dose, route and frequency The lidocaine 2% solution should be drawn up from the ampoule into a sterile syringe using an 18G (green) needle and aseptic technique. The skin at the injection site should be cleaned with an antiseptic solution/gel/alcohol swab and it must be allowed to evaporate (dry) before injection. Do not physically dry the site or remove the agent by the use of cotton wool. N. B. The maximum safe dose of 2% lidocaine is 10mL. When used for simultaneous removal and insertion of the 68mg etonogestrel contraceptive implant the volumes used for insertion (5mL) and removal (2mL) are lower than this threshold. For implant insertion: Lidocaine 2% is injected subcutaneously along the planned line of implant insertion on the medial aspect of the upper arm. The needle should be inserted subcutaneously and 0.5mL injected directly below the insertion point. UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
7 The needle should then be inserted subcutaneously in the line of implant insertion to its full length (3.5cm) and the syringe drawn back to confirm the tip is not within a blood vessel. Approximately 2.5mL of lidocaine 2% should be injected evenly along the subcutaneous needle track as the needle is withdrawn. Maximum dose for insertion under this PGD is 5mL. A sterile swab should be placed over the injection site in case of bleeding. For implant removal: Between 0.5-2mL lidocaine 2% is injected subcutaneously directly beneath the distal tip of the implant to be removed. Maximum dose for removal under this PGD is 2mL. The position for injection is identified by first pushing the proximal end of the implant distally and towards the skin surface. The lidocaine 2% should be injected beneath the position of the distal tip when this pressure is exerted. After 3 minutes the anaesthetic effect should be tested by light pressure on the overlying skin with the needle tip. The patient may be aware of pressure but should not feel any sharp sensation. If the area is numb, proceed with implant removal. If after a maximum of 2mL has been injected and a painful sharp sensation is still felt with needle pressure, refer to doctor. An increased local anaesthetic dose may be needed Concurrent medication Women on a therapeutic dose of anticoagulant drugs such as heparin or warfarin have a higher risk of bleeding/haematoma with subcutaneous injection and are not suitable for treatment under this PGD. The cardiac depressant effects of lidocaine are additive to those of other antiarrhythmic agents. Patients on these medicines must be referred to a doctor Adverse effects Subcutaneous injection of lidocaine 2% is associated with initial stinging followed by loss of sensation to pain in the injected area. The anaesthetic effect may last for minutes. There may be a continued awareness of touch/pressure in an effectively anaesthetised area. There may be transient local swelling and erythema at the injection site. Subcutaneous injection as described in 3.2 should not be associated with systemic side effects. Inadvertent intravascular injection may cause dizziness or paraesthesia. If this occurs, stop injecting, calmly call for assistance. Lidocaine 2% is rapidly metabolised and any symptoms should resolve in minutes. Allergy to lidocaine 2% is very rare. Symptoms include excessive pain, itching or swelling at injection site. Breathlessness and collapse with tachycardia and hypotension suggest anaphylaxis. Facilities and support should be available to manage collapse from toxicity or anaphylaxis. UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
8 The woman may need reassurance throughout the procedure. Hyperventilation or tachycardia due to anxiety may cause symptoms which may be wrongly attributed to the local anaesthetic. Adverse events will be reported to the Committee on Safety of Medicines via the yellow card scheme or on the website at and to the local risk management committee. Medical advice in cases of anaphylaxis Injections of IM adrenaline/epinephrine 1:1000 must be available to treat an anaphylactic reaction should this occur. Medical advice must be sought as soon as possible from a doctor if any patient develops any signs of hypersensitivity. If there is a delay in medical support arriving and the condition of the patient is deteriorating then an emergency ambulance must be called on 999 or direct via ambulance control or dial 2222 (hospital internal) according to local procedure, or seek urgent medical advice. (Refer to Patient Group Direction for the administration of adrenaline (epinephrine) in cases of suspected anaphylactic reactions by qualified health professionals). Treatment of overdose See Section 3.4 above, paragraph 3. Effects on ability to drive or operate machinery No effects on driving or operating machinery due to the lidocaine 2% injection itself. However, women may need to avoid activity which exerts pressure on the arm after implant insertion or removal Advice to patient (i) Advice should be given on what to expect and what to do for major and minor reactions. (ii) The adverse effects of lidocaine administration must be clearly explained to the patient before administration. (iii) The patient information leaflet contained in the medicine(s) should be made accessible to the patient/parent/guardian. Where this is unavailable, or unsuitable, sufficient information should be given to the patient/parent/guardian in a language that they can understand Follow up treatment Patients should not leave if they are feeling at all unwell without speaking to the nurse or midwife first. If necessary a doctor or the patient s GP should be contacted for advice. UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
9 4. Designated Staff Authorised To Administer Under This PGD Part B The following staff are authorised to administer the drug specified in this PGD without an individual medical prescription providing the patient falls into one of the categories listed in 2.2 of this PGD. Staff must be employed either directly by NHS Grampian, or contracted to provide NHS services, or providing services in partnership with NHS Grampian under the direction of this authorised PGD. (i) Registered nurse or midwife as recognised by the NMC. In addition the following requirements are necessary. Staff must: (i) agree to be professionally accountable for their work (Appendix 1). (ii) be competent to assess the patient s capacity to understand the nature and purpose of the administration in order for the patient to give or refuse consent. (iii) be aware of current treatment recommendations and be competent to discuss issues about the drug with the patient. (iv) have been trained and assessed as being competent in the administration of the drug. All staff will have access to the current PGD. (v) have undertaken an NHS e-anaphylaxis training session which includes basic life support (with annual updates) and covers all aspects of the identification and management of anaphylaxis. (vi) have immediate access to the appropriate equipment and drugs to treat anaphylaxis and have access to the current PGD for the management and treatment of anaphylaxis should this occur. (vii) maintain their skills, knowledge and their own professional level of competence in this area according to their individual Code of Professional Conduct. (viii) agree to work within the terms of the NHS Grampian PGD. Professional Managers/Nurse managers/lead nurses will be responsible for: (i) Ensuring that the current PGD is available to staff providing care under this direction. (ii) Ensuring that the staff have access to all relevant Scottish Government Health Directorate advice, including any relevant CMO letter(s). (iii) Ensuring that staff have received adequate training in all areas relevant to this PGD and meet the requirements above. (iv) Maintaining a current record of all staff authorised to administer the drug specified in this PGD. UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
10 5. Documentation 5.1. Authorisation of administration Nurses and midwives working in GP surgeries can be authorised to administer the drug specified in this PGD by practice GPs. (NB. GP Practices must have adopted NHS Grampian PGD for use in their practice). Nurses and midwives working within NHS Grampian can be authorised to administer the drug specified in this PGD by their nurse manager. Nurses and Midwives working within sexual health clinics can be authorised to administer the drug specified in this PGD by the Consultant in Sexual Health Services, NHS Grampian. A certificate of competence (Appendix 2) signed by the authorising doctor/manager should be supplied. This should be held in the individual nurse and midwives records or as agreed locally Record of administration An electronic or paper record for recording the screening of patients and the subsequent administration of the drug specified in this PGD must be completed in order to allow audit of practice. This should include: (i) Name and address of patient/parent/guardian/person with parental responsibility, Unit No/CHI No (ii) Date of birth (iii) Consultant/General Practitioner details (iv) Risk group, if appropriate (v) Physical examination required, if appropriate (vi) Exclusion criteria, record why drug not administered (vii) Reason for giving (viii) Consent to the administration (if not obtained elsewhere) (ix) Drug manufacturer, batch number, expiry date (x) Site where drug administered, dose and route of administration (xi) Signature and name in capital letters of practitioner who administered the drug (xii) Date drug given (xiii) Record of adverse effects (advise patient s doctor). These records should be retained: For children and young people, retain until the patient's 25th birthday or 26th if the young person was 17 at the conclusion of treatment. For 17 years and over retain for 6 years after last date of entry. Or for 3 years after death, or in accordance with local policy, where this is greater than above. UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
11 5.3. Consent Prior to the administration of the drug, consent must be obtained, preferably written, either from the patient, parent, guardian or person with parental responsibility and documented either in the patient s medical records/notes or on an administration form (see section 5.2). Consent must be in line with current NHSG Staff Policy for Obtaining Consent for Clinical Procedures and Healthcare Interventions. See link below Further Points The manufacturers leaflet inside boxes of drug should be read and advice from them taken into consideration. 7. Facilities And Supplies To Be Available At Sites For The Administration Of The Drug Specified In This PGD The following should be available at sites where the drug is to be administered: (i) Resuscitation equipment. (ii) Access to medical support (this may be via telephone). (iii) Safe storage areas for medicines and equipment. (iv) Approved equipment for the disposal of used materials. (v) Clean and tidy work areas. (vi) Copies of the current PGD for the drug specified in the PGD (vii) PGD for the administration of adrenaline (epinephrine) in cases of suspected anaphylactic reactions by qualified health professionals. 8. Audit All records of administration of the drug specified in this PGD will be filed with the normal records of medicines administration in each practice/service. A designated person within each CHP/practice/service will be responsible for auditing completion of drug forms and collation of data. UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
12
13 Appendix 1 Health Care Professional Agreement To Administer Medicines Under Patient Group Direction I: (Insert name) Working within: e.g. CHP, Practice Agree to administer medicines under the direction contained within the following Patient Group Direction Patient Group Direction For The Administration Of Lidocaine 2% Injection For The Insertion/Removal Of The 68mg Etonogestrel Contraceptive Implant By Nurses And Midwives Working Within NHS Grampian I have completed the appropriate training to my professional standards enabling me to administer medicines under the above Patient Group Direction. I agree not to act beyond my professional competence nor outwith the recommendations of the Patient Group Direction. Signed: Print Name: Date: HPC Registration No: UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
14 Appendix 2 Certificate Of Competence To Administer Medicines Under Patient Group Direction This authorises: Working within: e.g. CHP, Practice To administer medicines under the following Patient Group Direction Patient Group Direction For The Administration Of Lidocaine 2% Injection For The Insertion/Removal Of The 68mg Etonogestrel Contraceptive Implant By Nurses And Midwives Working Within NHS Grampian The above named person has satisfied the training requirements and is competent to administer medicines under the above Patient Group Direction. The above named person has agreed not to act beyond their professional competence nor outwith the recommendations of the Patient Group Direction Signed: Authorising Manager/Doctor Print Name: Date: UNCONTROLLED WHEN PRINTED Review Date: March 2015 Identifier: NHSG/PGD/lido_eton/MGPG
Yes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
Title: Patient Group Direction for the administration of lidocaine hydrochloride 1% injection as infiltration anaesthesia for insertion/removal of central venous catheters by nurses/radiographers working
More informationPatient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within NHS Grampian
Patient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within NHS Grampian Co-ordinators: Adapted from National PGD See Page 1 Consultation
More informationNHSG/PGD/SteroidInj/MGPG633. NHSG/PGD/SteroidInj/MGPG507
Title: Identifier: Replaces: Patient Group Direction for the administration of local corticosteroid injections and/or lidocaine by physiotherapists and radiographers working within NHS Grampian NHSG/PGD/SteroidInj/MGPG633
More informationYes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
Title: Identifier: Replaces: Across NHS Boards Patient Group Direction for the administration of adrenaline (epinephrine) in cases of suspected anaphylactic reactions by qualified health professionals
More informationEmergency Treatment of an Anaphylactic Reaction in the Community Protocol
Emergency Treatment of an Anaphylactic Reaction in the Community Protocol Reference Number: NHSCT/09/216 Responsible Directorate: Children s Services Replaces (if appropriate): Northern Trust Departmental
More informationClinical Performance Director of Nursing Allison Bussey
PGD 0314 Patient Group Direction Administration of Adrenaline (Epinephrine) 1:1000 (1mg/ml) Injection By Registered Nurses employed by South Staffordshire & Shropshire Healthcare Foundation NHS Trust This
More informationEmergency Treatment of Anaphylactic Reactions
Emergency Treatment of Anaphylactic Reactions Authorising Officer Signature Of Authorising Officer: Tom Cahill, Deputy Chief Executive Version: V3 Ratified By: HPFT Drugs and Therapeutic Committee Date
More informationMedicines Management
Medicines Management Patient Group Direction for the Supply/administration of Adrenaline (Epinephrine) for Treatment of Anaphylaxis by accredited community Pharmacists. Rationale To enable a pharmacist,
More informationCombined Child Diabetes
Title: Identifier: Replaces: Policy For The Adjustment Of Insulin Doses By Paediatric Diabetes Specialist Nurses Working With Children Within NHS Grampian N/A Across NHS Boards Organisation Wide Directorate
More informationDeveloped / Reviewed by the Collaborative Provider PGD (Patient Group Direction) Group (CPPGDG) and approved by the following members of the CPPGDG:
Patient Group Direction 7.02 version 4.0 Administration of Intravenous Adrenaline (Epinephrine) 1 in 10,000 (100micrograms per ml) Injection in Cardiopulmonary by Registered Practitioners in Torbay and
More informationPatient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.
Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written
More informationVersion Number: 5. Patient Group Direction originally drawn up by: Reviewed by: Patient Group direction authorised by: Medical Lead
PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY AND/OR ADMINISTRATION OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES WORKING IN COMMUNITY AND INPATIENT SUBSTANCE MISUSE TEAMS Version Number: 5 Patient
More informationCLINICAL PROTOCOL FOR THE USE OF INJECTED LOCAL ANAESTHETICS IN COMMUNITY TRUST SERVICES
CLINICAL PROTOCOL FOR THE USE OF INJECTED LOCAL ANAESTHETICS IN COMMUNITY TRUST SERVICES RATIONALE This clinical protocol outlines the injected local anaesthetics used by Trust services and the circumstances
More information2. Characteristics of staff Qualifications required. Additional requirements. Continued education & training requirements
Patient Group Direction The supply of Azithromycin 1g as a single dose by accredited Community Pharmacists to patients in receipt of a positive test result to Chlamydia trachomatis, and treatment of their
More informationDocument Title: Patient Group Direction for Adrenaline (Epinephrine) 1:1000. http://www.england.nhs.uk/mids-east/ss-at/immunisations/
Document Title: Patient Group Direction for Adrenaline (Epinephrine) 1:1000 Area Team Doc Ref.: PGD Version No.: 06/2014 Doc Ref.: Author: Owner: File Reference: Document Overseeing Group: http://www.england.nhs.uk/mids-east/ss-at/immunisations/
More informationpatient group direction
DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationTable of Contents. Page
Table of Contents 1.0 Purpose 3 2.0 Scope 3 3.0 Definition of Anaphylaxis 3 4.0 Recognition of Anaphylaxis: General Principles 3 5.0 Recognition of Anaphylactic Reaction 5 6.0 Treatment of Anaphylactic
More informationReview Group: Mental Health Operational Medicines Management Group. Signature Signature Signature. Review Date: December 2014
Mental Health NHS Grampian Mental Health Service Staff Guidance For The Prescribing Of Vitamin Supplementation During In-Patient Admission (Mental Health) For Alcohol Withdrawal Co-ordinators: Consultant
More informationChildren & Young People s Directorate. School Nursing Procedure For Administration of Immunisations
Children & Young People s Directorate School Nursing Procedure For Administration of Immunisations Author Mrs Gladys Bleakley & Mrs Barbara Ervine Directorate responsible for Children & Young Peoples this
More informationMULTI AGENCY POLICY FOR THE ADMINISTRATION OF MEDICATION AND HEALTH CARE PROCEDURES:
MULTI AGENCY POLICY FOR THE ADMINISTRATION OF MEDICATION AND HEALTH CARE PROCEDURES: Early years provision, Educational Establishments and Voluntary Services Document reference number: C O R P O L O 0
More informationNHS Professionals. Guidelines for the Administration of Medicines
NHS Professionals Guidelines for the Administration of Medicines Introduction The control of medicines in the United Kingdom is primarily through the Medicines Act (1968) and associated British and European
More information1. What Xylocaine with adrenaline is and what it is used for
Package leaflet: Information for the user Xylocaine 1% and 2% with adrenaline (epinephrine) 1:200,000 Solution for Injection lidocaine, adrenaline (epinephrine) Read all of this leaflet carefully before
More informationPRIMARY CARE PRACTICE GUIDELINES
1 of 6 1. OUTCOME To identify anaphylaxis in the primary care setting and provide an evidence informed emergency response utilizing the most current provincial and federal practice guidelines. 2. DEFINITIONS
More informationPatient Group Directions. Guidance and information for nurses
Patient Group Directions Guidance and information for nurses Patient Group Directions Guidance and information for nurses Contents Introduction 4 What is a patient group direction (PGD)? 4 When can PGDs
More informationVaccine Protocol Agreement. Name of Pharmacy: Address: City, State, Zip:
Vaccine Protocol Agreement Name of Pharmacy: Address: City, State, Zip: This Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses ( Nurses
More informationNational Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS Below is a template that can be used to produce a local patient group direction (PGD) for the administration of
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationInfluenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1)
Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) This Influenza Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses (
More informationSt Bernard s Catholic School. Administration of Medicine Policy
St Bernard s Catholic School Page 1 of 10 The St Bernard s administration of medicine policy has been developed to ensure that children with medical needs have the same access to education as their peers
More informationDocument Title: PCT Doc Ref.: Version No.: 1/2014. Local Doc Ref.:
Document Title: Patient Group Direction (PGD) for the vaccination of pregnant women (gestation week 28 onwards) and new mothers against pertussis (Whooping Cough) using Boostrix-IPV (Diphtheria, tetanus,
More informationUBISTESIN 1:200,000 and UBISTESIN FORTE 1:100,000
UBISTESIN 1:200,000 and UBISTESIN FORTE 1:100,000 Articaine hydrochloride and adrenaline hydrochloride Consumer Medicine Information WHAT IS IN THIS LEAFLET Please read this leaflet carefully before you
More informationDirection Number: - NECSAT 2014/008
Patient Group Direction (PGD) for the Administration of ADRENALINE (Epinephrine) INJECTION For The TREATMENT of ANAPHYLAXIS by Registered Professionals to Individuals Accessing NHS Services in Durham,
More information2014 Supporting Students at School with Medical Conditions Policy
2014 Supporting Students at School with Medical Conditions Policy Review Framework The policy should be reviewed every four years This policy was created in: This issue was revised and released on: School
More informationMedications or therapeutic solutions may be injected directly into the bloodstream
Intravenous Therapy Medications or therapeutic solutions may be injected directly into the bloodstream for immediate circulation and use by the body. State practice acts designate which health care professionals
More informationAnaphylaxis. Exceptional healthcare, personally delivered
Anaphylaxis Exceptional healthcare, personally delivered 2 Introduction Anaphylaxis (also known as anaphylactic shock) is a severe, potentially fatal allergic reaction. Anaphylaxis is caused by your body
More informationEMERGENCY TREATMENT OF ANAPHYLAXIS EPINEPHRINE AUTO-INJECTOR
I. GENERAL GUIDELINES EMERGENCY TREATMENT OF ANAPHYLAXIS EPINEPHRINE AUTO-INJECTOR A. PURPOSE To counteract a severe allergic reaction (anaphylaxis) to a foreign substance as prescribed by the licensed
More informationAnaphylaxis and other adverse events
Anaphylaxis and other adverse events Aim: To be able to manage anaphylaxis and other adverse events correctly Learning outcomes Define local and systemic adverse events Distinguish between anaphylaxis
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully before you start using this
More informationMEDICATION MANUAL Policy & Procedure
MEDICATION MANUAL Policy & Procedure TITLE: Section: Initial Management of Anaphylaxis Following Immunization Medication Specific NUMBER: MM 20-005 Date Issued: October 2009 Source: Distribution: Capital
More informationRivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationUncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser
Acute Sector NHS Grampian Staff Local Treatment Protocol For Venous Thromoboembolic Prophylaxis Using Rivaroxaban 10mg Tablets In Adult Patients Undergoing Elective Hip Or Knee Replacement Surgery. Lead
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK ACAMPROSATE CALCIUM (Campral EC) for alcohol abstinence ESCA: Adjunct in the treatment of chronic alcohol dependence (under
More informationUncontrolled When Printed. Version 1.1. Consultation Group: Approver: Co-ordinators: Grampian Medicines Management Group. Deputy Director of Pharmacy
NHS Grampian Staff Policy For Patients To Receive Aspects Of Their Treatment Through Private Healthcare Providers (Co-Payments) In Respect Of Medicines Co-ordinators: Deputy Director of Pharmacy Consultation
More information8/6/2010. Name of medication Concentration (1:1,000 or 1mg/1ml) Expiration date
Learning Objectives: Anaphylaxis & Epinephrine Administration by the EMT Adapted with permission from the Pilot Project for the Administration of Epinephrine by Washington EMTs With successful completion
More informationManagement of an anaphylactic reaction to Omalizumab (Xolair) drug therapy
Management of an anaphylactic reaction to Omalizumab (Xolair) drug therapy Turnberg Building Respiratory Medicine 0161 206 3158 All Rights Reserved 2014. Document for issue as handout. What is an allergic
More informationStowe School Medications Policy
INTRODUCTION Most pupils will need medication at some stage of their school life. Although this will mainly be for short periods there are a few pupils with chronic conditions who may require regular medication
More informationIntroduction. Definition
DIRECTIVES FOR PRIVATE AMBULATORY SURGICAL CENTRES PROVIDING AMBULATORY SURGERY: REGULATION 4(1) OF THE PRIVATE HOSPITALS AND MEDICAL CLINICS REGULATIONS [CAP 248, Rg 1] I Introduction 1 These directives
More informationAdministration of Medications & Fluids via a Peripheral Intravenous Cannula
Administration of Medications & Fluids via a Peripheral Intravenous Cannula Clinical S.O.P. No.: 22.0 Compiled by: Approved by: Review date: November 2016 Administration of Medications & Fluids via S.O.P.
More informationCare Pathway for the Administration of Intravenous Iron Sucrose (Venofer )
Departments of Haematology, Nephrology and Pharmacy Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer ) [Care Pathway Review Date] Guidance for use This Care Pathway is intended
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (HCl) STEROP 0,8mg/1ml. Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (HCl) STEROP 0,4mg/1ml ADRENALINE (HCl) STEROP 0,8mg/1ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully
More informationGuidance for the Detoxification of Alcohol Dependent Patients in Community or Outpatient Settings
Title: Identifier: Replaces: Guidance for the Detoxification of Alcohol Dependent Patients in Community or Outpatient Settings NHSG/Guid/Detox_ADP/MGPG663 N/A - New document Across NHS Boards Organisation
More informationADMINISTRATION OF DRUG PRODUCTS/MEDICATIONS TO STUDENTS
ADMINISTRATION OF DRUG PRODUCTS/MEDICATIONS TO STUDENTS 453.4 Drug products/medications are given to students in the school setting to continue or maintain a medical therapy which promotes health, prevents
More informationObjectives At the completion of this module, unlicensed assistive personnel (UAP) should be able to:
Objectives At the completion of this module, unlicensed assistive personnel (UAP) should be able to: 1. administer medications by subcutaneous injections. 2. document medication administration in the client
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin
PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because
More informationPackage leaflet : information for the user. Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.
Package leaflet : information for the user Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.1mg per ml Because of your condition it may not be possible for
More informationBEAUMONT HOSPITAL DEPARTMENT OF NEPHROLOGY RENAL BIOPSY
1 BEAUMONT HOSPITAL DEPARTMENT OF NEPHROLOGY GUIDELINES ON ADMINISTRATION OF INTRAVENOUS IRON SUCROSE (VENOFER) AS A BOLUS DOSE IN THE RENAL OUTPATIENT SETTING Date Developed: August- October 2007 RENAL
More informationAn introduction to the principles and practice of safe and effective administration of injections
An introduction to the principles and practice of safe and effective administration of injections Introduction Giving an injection safely is considered to be a routine nursing activity. However it requires
More informationClinical Guideline For The Use of Rectus Sheath Catheters For The Management of Pain Following Laparotomy. 1. Aim/Purpose of this Guideline
Clinical Guideline For The Use of Rectus Sheath Catheters For The Management of Pain Following Laparotomy. 1. Aim/Purpose of this Guideline 1.1. Nursing guidelines for the use of rectus sheath catheters
More informationProtocol for Management of Suspected Anaphylactic Shock
Protocol for Management of Suspected Anaphylactic Shock COMMUNICABLE DISEASE CONTROL Summary of First Steps for Suspected Anaphylaxis Signs and Symptoms: Within minutes signs/symptoms can develop and do
More informationCardiac Catheter Lab Information for patients having a Coronary Angiogram
Cardiac Catheter Lab Information for patients having a Coronary Angiogram Page 1 of 5 What is a Coronary Angiogram? This is a test that uses dye and special x-rays to show the inside of your coronary arteries.
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationHumulin R (U500) insulin: Prescribing Guidance
Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring
More informationRivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)
Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep
More informationAnaphylaxis: Treatment in the Community
: Treatment in the Community is likely if a patient who, within minutes of exposure to a trigger (allergen), develops a sudden illness with rapidly progressing skin changes and life-threatening airway
More informationWilliam MacGregor Primary School. Medical Administration Policy
William MacGregor Primary School Medical Administration Policy School Vision In accordance with our aim to be a Rights Respecting School, this policy supports the following articles of the United Nation
More informationSTANDARD OPERATING PROCEDURE. Administration of High Dose Muscular Vitamin Supplements for Undergoing Alcohol
STANDARD OPERATING PROCEDURE Administration of High Dose Muscular Vitamin Supplements for Undergoing Alcohol DOCUMENT CONTROL: Version: 2 Ratified by: Clinical Effectiveness Committee Date ratified: 03
More informationA. ADMINISTERING SUBCUTANEOUS MEDICATIONS INTERMITTENTLY/CONTINUOUSLY B. (SUBCUTANEOUS INFUSION) HYDRODERMOCLYSIS
SUBCUTANEOUS THERAPY A. ADMINISTERING SUBCUTANEOUS MEDICATIONS INTERMITTENTLY/CONTINUOUSLY B. (SUBCUTANEOUS INFUSION) HYDRODERMOCLYSIS PARTS I. Purposes II. General Information III. Responsibilities IV.
More informationGuideline for the Safe Handling and Administration of Subcutaneous Cyotoxic Chemotherapy for Adults in the Community Setting
Guideline for the Safe Handling and Administration of Subcutaneous Cyotoxic Chemotherapy for Adults in the Community Setting Guideline for the Safe Handling and Administration of Subcutaneous Cyotoxic
More informationAVOIDING UNPLANNED ADMISSIONS ENHANCED SERVICE: PROACTIVE CASE FINDING AND CARE REVIEW FOR VULNERABLE PEOPLE GUIDANCE AND AUDIT REQUIREMENTS
April 2014 AVOIDING UNPLANNED ADMISSIONS ENHANCED SERVICE: PROACTIVE CASE FINDING AND CARE REVIEW FOR VULNERABLE PEOPLE GUIDANCE AND AUDIT REQUIREMENTS A programme of action for general practice and clinical
More informationStandards for medicines management Guidance for nurses and midwives
Record keeping Standards for medicines management Guidance for nurses and midwives 1 15105_Record Keeping_A5_proof 3.indd 1 09/03/2010 09:47 We are the nursing and midwifery regulator for England, Wales,
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationAlert. Patient safety alert. Actions that can make anticoagulant therapy safer. 28 March 2007. Action for the NHS and the independent sector
Patient safety alert 18 Alert 28 March 2007 Immediate action Action Update Information request Ref: NPSA/2007/18 4 Actions that can make anticoagulant therapy safer Anticoagulants are one of the classes
More informationEpiPen Use. When should I use the EpiPen?
What is an EpiPen? EpiPen is an emergency device that can inject adrenaline. It is used to treat severe allergic reactions (anaphylaxis). Adrenaline, (a naturally occurring hormone) reverses the severe
More information1 What Anapen is and what it is used for?
PACKAGE LEAFLET: INFORMATION FOR THE USER Anapen 500 micrograms in 0.3 ml solution for injection (pre-filled syringe) Adrenaline (Epinephrine) Auto-Injector Read all of this leaflet carefully before you
More informationPROCEDURE FOR THE ADMINISTRATION OF MEDICATION BY INJECTION VIA THE INTRAMUSCULAR ROUTE OR VIA THE SUBCUTANEOUS ROUTE
PROCEDURE FOR THE ADMINISTRATION OF MEDICATION BY INJECTION VIA THE INTRAMUSCULAR OR VIA THE SUBCUTANEOUS First Issued Issue Version Purpose of Issue/Description of Change Planned Review Date October 2012
More informationSTANDARDIZED PROCEDURE BONE MARROW ASPIRATION
I. Definition: This protocol covers the task of bone marrow aspiration by an Allied Health Professional. The purpose of this standardized procedure is to allow the Allied Health Professional to safely
More informationDepartment of Education and Children Rheynn Ynsee as Paitchyn. Guidance for Schools on the Administration of Medication and Medical Care
Department of Education and Children Rheynn Ynsee as Paitchyn Guidance for Schools on the Administration of Medication and Medical Care May 2010 0 This Document updates the Department of Education and
More informationANAPHYLAXIS. Introduction. Differential Diagnosis. Starship Children s Health Clinical Guideline
Introduction Differential Diagnosis Management Treatment of Anaphylaxis (Flow Chart) Disposition from Emergency Department Adrenaline Autoinjectors Action Plan Adrenaline Autoinjector Information Sheet
More informationGuidelines and Procedure for the Safe Administration and Management of Medicines
Appendix 7 Guidelines and Procedure for the Safe Administration and Management of Medicines 1. INTRODUCTION 1.1 This procedure must be read in conjunction with the Policy for the Administration of Medication
More informationSuturing Policy for Nurses in Emergency Departments
This is an official Northern Trust policy and should not be edited in any way Suturing Policy for Nurses in Emergency Departments Reference Number: NHSCT/12/545 Target audience: Registered Nurses Sources
More informationGiving Yourself Dalteparin (Fragmin) or Heparin
Contents www.bcwomens.ca What is Dalteparin (Fragmin)...1 Where do I get this medication from?...1 How often do I give myself this medication?...1 Side effects...1 Steps to Giving Yourself Dalteparin (Fragmin)..1
More informationBrewton City Schools Anaphylaxis Preparedness Guidelines
Brewton City Schools Anaphylaxis Preparedness Guidelines Background In response to Act#2014-405 by the Alabama Legislature, the Brewton City School System recognizes the growing concern with severe life-threatening
More informationSection 400: Code # 453.4R
Section 400: Code # 453.4R Administering Medication Conditions for Administering Prescription Drugs Except as otherwise specifically provided by law, a school bus driver, employee, or volunteer that has
More informationALLERGENIC EXTRACT. Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE. U.S. Government License No.
ALLERGENIC EXTRACT Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE U.S. Government License No. 308 Revised 07/04 PO Box 800 Lenoir, NC 28645 USA DESCRIPTION This set
More informationAnaphylaxis before and after the emergency
Anaphylaxis before and after the emergency Mike Levin Paediatric Asthma and Allergy Division University of Cape Town Red Cross Hospital michael.levin@uct.ac.za http://www.scah.uct.ac.za/scah/clinicalservices/medical/allergy
More informationAppendix 7 Anaphylaxis Management
Appendix 7 Anaphylaxis Management Anaphylaxis: Initial Management in Non-Hospital Settings This section is intended for the initial management of patients in a public health clinic, medical office or similar
More informationHow To Take Xarelto
A patient's guide Your clinic's contact details are: Name: Contact number: Contents 2 Why have I been prescribed Xarelto? 2 What is Xarelto? 3 How do I take Xarelto? 3 What should I do if I miss a dose
More informationRecommended guidelines for. schools
Recommended guidelines for medication administration in schools Objective At the end of the session the nurses will be aware of the HAAD standards and roles and responsibilities of a nurse in medication
More informationPolicy For The Adjustment Of Insulin Dose For Patients With Diabetes By Diabetes Specialist Dietitians And Cystic Fibrosis Dietitians In NHS Grampian
Policy For The Adjustment Of Insulin Dose For Patients With Diabetes By Diabetes Specialist Dietitians And Cystic Fibrosis Dietitians In NHS Grampian Co-ordinators: Advanced Dietitian (Diabetes) Consultation
More informationInformation for you Abortion care
Information for you Abortion care Published in February 2012 This information is for you if you are considering having an abortion. It tells you: how you can access abortion services the care you can expect
More informationTERMINATION OF PREGNANCY- MEDICAL
TERMINATION OF PREGNANCY- MEDICAL Information Leaflet Your Health. Our Priority. Page 2 of 8 You have been offered a medical termination of pregnancy using mifepristone. You will have been given some verbal
More informationSecretary Approval Cardiac Arrest frequently asked questions
Secretary Approval Cardiac Arrest frequently asked questions Secretary Approval Cardiac Arrest - frequently asked questions 1. What is a Secretary approval? Some regulations within the Drugs, Poisons and
More informationPolicy Document Control Page
Policy Document Control Page Title Title: Covert Administration of Medicines Version: Version 6 Reference Number: CL37 Supersedes Supersedes: Version 5 Description of amendment(s): Originator 3.5 Clarification
More informationAdministration of Medicines and Healthcare Needs Policy
Administration of Medicines and Healthcare Needs Policy 2014-15 TO BE REVIEWED BY GOVERNORS SUPPORT COMMITTEE Reviewed in: November 2014 Next Review Date: November 2015 This college policy compliments/reflects
More informationAdministration of Medicines and Healthcare Needs in Schools
Administration of Medicines and Healthcare Needs in Schools The administration of medicines by staff remains a voluntary activity. Employees who volunteer to assist with any form of medical procedure are
More informationTABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS
TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS Section 1. Authority 9-1 Section 2. Definitions 9-1 Section 3. Patient Profile Records 9-1 Section 4. Prospective
More informationPARENT/GUARDIAN REQUEST: ADMINISTRATION OF EMERGENCY EPINEPHRINE, ANAPHYLAXIS CARE PLAN/ IHP & IEHP
IEF Elementary School 105 Andrew Street, Green Brook, N.J. 08812 School Nurse: Mrs. Ostrander Office Phone: 732-9681052 ext. # 3 Fax: 732-968-0791 Green Brook Township Public Schools Green Brook Middle
More informationNHS Lanarkshire Care Homes Protocol Group. Care Home Prescriptions - Good Practice Guide
NHS Lanarkshire Care Homes Protocol Group Care Home Prescriptions - Good Practice Guide Date of Publication Review Date August 2015 Responsible Author Francesca Aaen Care Homes Pharmacist on behalf of
More informationHealth Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 2 Hospital Pharmacy Standards of Practice Table of Contents 1. Application 2. Definitions 3. Drug Distribution 4. Drug Label 5. Returned Drugs 6. Drug Transfer
More informationORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE)
ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has
More information